October 2000 recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding the use of four licensed DTaP vaccines for infants and young children. The report supplements prior statements and summarizes data on the reactogenicity of acellular pertussis vaccines when administered as the fourth and fifth consecutive doses. It details observed increases in local reactions and limb swelling with later doses and provides guidance on vaccine brand consistency.
Use Cases
- Analyzing trends in local vaccine reactions based on the described increases in frequency and magnitude with dose number.
- Studying historical vaccine licensing and recommendations based on the four named DTaP products and their approved dosing schedules.
- Modeling vaccine interchangeability policies based on the ACIP recommendation for using the same brand when feasible.
Strengths
- Provides specific temporal context with a reference date of October 2000.
- Names four specific licensed DTaP vaccine products (ACEL-IMUNE, Tripedia, Infanrix, Certiva) and their manufacturers.
- Summarizes concrete safety observations, including extensive limb swelling after the fourth and fifth doses for multiple products.
Limitations
- Row count is unknown, which may limit suitability assessment.
- Column-level documentation is absent; field semantics must be inferred after download.
- Last update date is unknown; freshness unverified.
Provenance
- Source
- Advisory Committee on Immunization Practices (ACIP)
- Collection Method
- Likely a published report or statement.
- Time Range
- Circa October 2000
- Geography
- United States